Remove Ablation Remove Arrhythmia Remove Risk Factors
article thumbnail

News from EHRA 2024: International Experts Agree on Standards for Catheter Ablation of Atrial Fibrillation

DAIC

An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany. Image courtesy: European Society of Cardiology.

article thumbnail

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

DAIC

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.

article thumbnail

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation

DAIC

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.

Ablation 105
article thumbnail

Risk factors of late arrhythmia recurrences during 12 months after catheter ablation of atrial fibrillation: Insight into atrial cardiomyopathy

HeartRhythm

A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrial fibrillation (AF) is still reported.1 A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrial fibrillation (AF) is still reported.1

article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. 1,ii For patients who had received ablation, median procedure and fluoroscopy times were 90.0 Food & Drug Administration ( FDA ).

article thumbnail

Asthma is Associated with Higher Recurrence Rates of Atrial Fibrillation Following Catheter Ablation

HeartRhythm

Asthma is a known risk factor for atrial fibrillation (AF), the most common sustained arrhythmia. While radiofrequency catheter ablation is effective in treating AF, the impact of asthma and its severity on ablation outcomes has not been previously explored.

article thumbnail

PO-01-156 UNVEILING CLINICAL AND IMAGING PREDICTORS OF VENTRICULAR TACHYCARDIA ABLATION OUTCOMES IN STRUCTURAL HEART DISEASE PATIENTS: INSIGHTS FROM MULTIVARIATE ANALYSIS OF 508 PROCEDURES

HeartRhythm

Multiple risk factors for arrhythmia recurrence after Ventricular Tachycardia (VT) ablation have been identified. However, the cumulative impact of these risk factors has not been evaluated, making it challenging to predict these risks in patients with multiple coexisting conditions.